NIKKEI 225
38,011.19 +49.39 (+0.13%) HANG SENG
16,394.73 +142.89 (+0.88%) CRUDE OIL
82.78 +0.09 (+0.11%) GOLD FUTURES
2,384.40 -4.00 (-0.17%) DOW
37,753.31 -45.66 (-0.12%) Bitcoin GBP
49,360.98 -1,893.95 (-3.70%)
Transgene SA (TRGNF)
| Previous close | 1.6200 |
| Open | 1.6200 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.6200 - 1.6200 |
| 52-week range | 1.6200 - 2.1000 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 163.382M |
| Beta (5Y monthly) | 0.72 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3800 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireAvailability of Transgene's 2023 Universal Registration Document
TRANSGENE (Paris: TNG) today announced that its Universal registration document for the fiscal year ended December 31, 2023, was submitted to the French stock market authority (Autorité des Marchés financiers – AMF) in ESEF format and registered under the reference D.24-0274. The 2023 Universal Registration Document is available to the public under the conditions provided by applicable regulations. The document is available on the Company’s website: www.transgene.fr, in the “Investors/Financial
GlobeNewswireTransgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers. All treated patients remain disease-free after a median follow-up of 18.6 months. Phase II part of the trial to start enrolling patients in coming weeks. Strasbourg, France & Tokyo, Japan, April 9, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation
GlobeNewswireTransgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
2023 Full-year results and business update Lead program TG4050 to deliver data in 2024. Advancements in other clinical programs and Research and Innovation (R&I) activity to deliver news flow and fuel growth in Transgene’s portfolio over the next 24 months.New leadership team focused on successfully delivering TG4050 and portfolio products to patients.Extended financial visibility secured until Q4 2025 through a revised credit facility provided by the major shareholder Institut Mérieux. Conferen
